HRP20171708T1 - FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID - Google Patents
FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID Download PDFInfo
- Publication number
- HRP20171708T1 HRP20171708T1 HRP20171708TT HRP20171708T HRP20171708T1 HR P20171708 T1 HRP20171708 T1 HR P20171708T1 HR P20171708T T HRP20171708T T HR P20171708TT HR P20171708 T HRP20171708 T HR P20171708T HR P20171708 T1 HRP20171708 T1 HR P20171708T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- pharmacologically active
- active ingredient
- dosage form
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Farmaceutski pripravak naznačen time da je za uporabu za sprječavanje ili liječenje boli koji sadrži:
a) prvi farmakološki aktivni sastojak izabran od spoja prema kemijskoj formuli (I) i njihove fiziološki prihvatljive soli
[image]
i
b) drugi farmakološki aktivni sastojak izabran od gabapentinoida i njihovih fiziološki prihvatljivih soli.
2. Farmaceutski pripravak za uporabu za sprječavanje ili liječenje boli prema zahtjevu 1, naznačen time da je prvi farmakološki aktivni sastojak spoj prema kemijskoj formuli (I)
[image]
3. Farmaceutski pripravak za uporabu za sprječavanje ili liječenje boli prema zahtjevu 1 ili 2, naznačen time da je drugi farmakološki aktivni sastojak odabran iz skupine koja sadrži pregabalin, gabapentin, vigabatrin i njihove fiziološki prihvatljive soli.
4. Farmaceutski pripravak za uporabu za sprječavanje ili liječenje boli prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži prvi i drugi farmakološki aktivni sastojak u takvom masenom omjeru da će nakon davanja pacijentu imati sinergističko terapeutsko djelovanje.
5. Farmaceutski pripravak za uporabu za sprječavanje ili liječenje boli prema bilo kojem od prethodnih zahtjeva, naznačen time da je relativni omjer mase prvog farmakološki aktivnog sastojka prema drugom farmakološki aktivnom sastojku unutar raspona od 1:30 do 1 : 1,000,000.
6. Farmaceutski pripravak za uporabu za sprječavanje ili liječenje boli prema zahtjevu 5, naznačen time da bol je:
- periferna, središnja ili mišićna skeletna bol; i/ili
- akutna, subakutna ili kronična bol; i/ili
- umjerena do jaka bol; i/ili
- neuropatska ili psihogena ili nociceptivna ili miješana bol; i/ili
- bol u donjem dijelu leđa, visceralna bol ili glavobolja; i/ili
- postoperativna (post-kirurška) bol, rak ili upalna bol
7. Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli naznačen time da sadrži farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva.
8. Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema zahtjevu 7, naznačen time da sadrži prvi farmakološki aktivni sastojak u dozi od 10 do 1,200 µg.
9. Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema zahtjevu 7 ili 8, naznačen time da sadrži drugi farmakološki aktivni sastojak u dozi od 0.05 do 5 g.
10. Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema bilo kojem od zahtjeva 7 do 9, naznačen time da je doziranje prvog farmakološki aktivnog sastojka u rasponu od 1:20 do 20:1 količine koja je ekvivalentno djelotvorna doziranju drugog farmakološki aktivnog sastojka.
11. Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema bilo kojem od zahtjeva 7 do 10, naznačen time da je za oralnu, intravensku, intraperitonealnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu ili rektalnu primjenu.
12. Komplet za uporabu za sprječavanje ili liječenje boli koji sadrži prvi farmaceutski oblik doziranja koji sadrži prvi farmakološki aktivni sastojak kako je definiran u zahtjevu 1 ili 2, te drugi farmaceutski oblik doziranja koji sadrži drugi farmakološki aktivni sastojak kako je definiran u patentnom zahtjevu 1 ili 3.
13. Komplet za uporabu za sprječavanje ili liječenje boli prema zahtjevu 12, naznačen time da su prvi i drugi farmaceutski oblik doziranja prilagođeni za istovremenu ili uzastopnu primjenu, bilo istim ili različitim putem primjene.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003940 | 2012-05-18 | ||
| EP13726111.1A EP2849748B1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a gabapentinoid |
| PCT/EP2013/001465 WO2013170966A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a gabapentinoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171708T1 true HRP20171708T1 (hr) | 2017-12-29 |
Family
ID=48539081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171708TT HRP20171708T1 (hr) | 2012-05-18 | 2013-05-16 | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9320725B2 (hr) |
| EP (1) | EP2849748B1 (hr) |
| JP (1) | JP6116673B2 (hr) |
| CN (1) | CN104284658A (hr) |
| AU (1) | AU2013262072B2 (hr) |
| BR (1) | BR112014028574A2 (hr) |
| CA (1) | CA2873624A1 (hr) |
| CY (1) | CY1119777T1 (hr) |
| DK (1) | DK2849748T3 (hr) |
| EA (1) | EA029766B1 (hr) |
| ES (1) | ES2658218T3 (hr) |
| HR (1) | HRP20171708T1 (hr) |
| HU (1) | HUE034659T2 (hr) |
| IL (1) | IL235658A (hr) |
| LT (1) | LT2849748T (hr) |
| MX (1) | MX356245B (hr) |
| NO (1) | NO2849748T3 (hr) |
| PL (1) | PL2849748T3 (hr) |
| PT (1) | PT2849748T (hr) |
| RS (1) | RS56799B1 (hr) |
| SI (1) | SI2849748T1 (hr) |
| WO (1) | WO2013170966A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| CA2974578C (en) | 2015-01-23 | 2020-11-17 | Grunenthal Gmbh | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| JP7373904B2 (ja) | 2016-02-29 | 2023-11-06 | パーク・セラピューティクス・インコーポレイテッド | セブラノパドールの滴定 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US20030056896A1 (en) | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
| US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| WO2004047844A1 (en) | 2002-11-26 | 2004-06-10 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
| US20040222123A1 (en) | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
| CN1245379C (zh) | 2003-10-30 | 2006-03-15 | 曹桂东 | 加巴喷丁的制法 |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| BRPI0511941A (pt) | 2004-06-09 | 2008-01-22 | Pfizer | uso de (s, s)-reboxetina ou reboxetina racêmica |
| GB0412878D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Use |
| US8093408B2 (en) | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
| US20080014271A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| JP2008106028A (ja) | 2006-10-26 | 2008-05-08 | Boehringer Ingelheim Internatl Gmbh | 慢性疼痛の治療におけるフリバンセリンの使用 |
| US20080153874A1 (en) | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| WO2008108639A1 (en) | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
| EP1977744A1 (en) | 2007-04-03 | 2008-10-08 | Chemo Ibérica, S.A. | Polymorphic Form alpha of (S)-Pregabalin and process for its preparation |
| MX2010006608A (es) | 2007-12-21 | 2010-10-05 | Paz Arzneimittelentwicklung | Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor. |
| EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| EA201170356A1 (ru) | 2008-05-28 | 2011-08-30 | Плива Хрватска Д.О.О. | Полиморфные и аморфные формы лакозамида и аморфные композиции |
| SI2735338T1 (sl) * | 2008-09-05 | 2019-04-30 | Grunenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina |
| DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
| CA2805371C (en) * | 2010-07-30 | 2017-10-31 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
| RS54438B1 (sr) * | 2010-08-04 | 2016-06-30 | Grünenthal GmbH | Farmaceutski dozni oblik koji sadrži 6`-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-amina |
| DK2600846T3 (en) * | 2010-08-04 | 2016-01-11 | Gruenenthal Gmbh | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-fluoro- (N-methyl or N, N-dimethyl -) - 4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3 , 4, b] indole] -4-amine |
| PE20131096A1 (es) * | 2010-08-04 | 2013-10-10 | Gruenenthal Chemie | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
-
2013
- 2013-05-13 US US13/892,968 patent/US9320725B2/en active Active
- 2013-05-16 BR BR112014028574A patent/BR112014028574A2/pt not_active IP Right Cessation
- 2013-05-16 CA CA2873624A patent/CA2873624A1/en not_active Abandoned
- 2013-05-16 JP JP2015511952A patent/JP6116673B2/ja active Active
- 2013-05-16 AU AU2013262072A patent/AU2013262072B2/en not_active Ceased
- 2013-05-16 EA EA201401268A patent/EA029766B1/ru not_active IP Right Cessation
- 2013-05-16 PT PT137261111T patent/PT2849748T/pt unknown
- 2013-05-16 ES ES13726111.1T patent/ES2658218T3/es active Active
- 2013-05-16 HR HRP20171708TT patent/HRP20171708T1/hr unknown
- 2013-05-16 EP EP13726111.1A patent/EP2849748B1/en not_active Not-in-force
- 2013-05-16 WO PCT/EP2013/001465 patent/WO2013170966A1/en not_active Ceased
- 2013-05-16 RS RS20180083A patent/RS56799B1/sr unknown
- 2013-05-16 MX MX2014012764A patent/MX356245B/es active IP Right Grant
- 2013-05-16 CN CN201380025640.1A patent/CN104284658A/zh active Pending
- 2013-05-16 HU HUE13726111A patent/HUE034659T2/en unknown
- 2013-05-16 PL PL13726111T patent/PL2849748T3/pl unknown
- 2013-05-16 NO NO13726111A patent/NO2849748T3/no unknown
- 2013-05-16 DK DK13726111.1T patent/DK2849748T3/en active
- 2013-05-16 LT LTEP13726111.1T patent/LT2849748T/lt unknown
- 2013-05-16 SI SI201330920T patent/SI2849748T1/en unknown
-
2014
- 2014-11-12 IL IL235658A patent/IL235658A/en active IP Right Grant
-
2016
- 2016-03-15 US US15/070,797 patent/US9629825B2/en active Active
-
2018
- 2018-01-16 CY CY20181100050T patent/CY1119777T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX356245B (es) | 2018-05-21 |
| EA029766B1 (ru) | 2018-05-31 |
| EP2849748B1 (en) | 2017-11-01 |
| HUE034659T2 (en) | 2018-02-28 |
| HK1204943A1 (en) | 2015-12-11 |
| JP6116673B2 (ja) | 2017-04-19 |
| ES2658218T3 (es) | 2018-03-08 |
| US9320725B2 (en) | 2016-04-26 |
| EA201401268A1 (ru) | 2015-06-30 |
| RS56799B1 (sr) | 2018-04-30 |
| SI2849748T1 (en) | 2018-02-28 |
| CN104284658A (zh) | 2015-01-14 |
| WO2013170966A1 (en) | 2013-11-21 |
| PT2849748T (pt) | 2018-02-07 |
| US9629825B2 (en) | 2017-04-25 |
| CY1119777T1 (el) | 2018-06-27 |
| MX2014012764A (es) | 2014-11-21 |
| DK2849748T3 (en) | 2017-12-04 |
| IL235658A0 (en) | 2015-01-29 |
| BR112014028574A2 (pt) | 2017-06-27 |
| CA2873624A1 (en) | 2013-11-21 |
| AU2013262072A1 (en) | 2015-01-22 |
| AU2013262072B2 (en) | 2018-01-18 |
| LT2849748T (lt) | 2018-01-25 |
| US20130310434A1 (en) | 2013-11-21 |
| PL2849748T3 (pl) | 2018-03-30 |
| NO2849748T3 (hr) | 2018-03-31 |
| US20160193183A1 (en) | 2016-07-07 |
| EP2849748A1 (en) | 2015-03-25 |
| IL235658A (en) | 2017-07-31 |
| JP2015516446A (ja) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| JP2018505169A5 (hr) | ||
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| JP2012236834A5 (hr) | ||
| HRP20171708T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| WO2015035410A8 (en) | Cancer therapy | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| TW201129361A (en) | Methods for treating pain | |
| WO2012064159A3 (ko) | 항암용 조성물 | |
| HRP20171725T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR | |
| HRP20171922T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano [3,4,b]indol]-4-amin i duloksetin | |
| HRP20170517T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv |